BIRC2 and plasma cell myeloma: In another report using c-IAP1 and c-IAP2 double-deficient multiple myeloma cells or SMAC mimetics, it was found that c-IAP1 and -2 share the ability to repress the non-canonical NF-κB pathway at the level of the inhibitory complex [33].